ArticleFrontiers in microbiology2025
Exploring the antibacterial and anti-biofilm properties of Diacerein against methicillin-resistant
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic photothermal antibacterial efficacy and high biocompatibility of silver-carbon core-shell nanoparticles.Discover nano · 2026Article
- Antibacterial mechanism of hyper-branched poly-L-lysine against methicillin-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methicillin-resistant Methods: The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of DIA, as well as in - vitro combination susceptibility testing, were determined using the broth microdilution method. Additionally, resistance induction assays, time-growth curve measurements, membrane fluidity, intracellular protein levels, and reactive oxygen species (ROS) were assessed. The inhibition and clearance of MRSA biofilms by DIA were evaluated using the crystal violet staining method, with bacterial morphology and biofilms observed via scanning electron microscopy and confocal laser scanning microscopy. Finally, transcriptome analysis was conducted to identify gene expression changes in MRSA treated with DIA, and RT-qPCR verification was performed. Results: The MIC and MBC of DIA against MRSA were 32 μg/mL and 128 μg/mL, respectively, and synergistic antibacterial effects when combined with ampicillin. DIA increased intracellular ROS levels and membrane fluidity in MRSA, decreased soluble protein synthesis, and altered bacterial morphology. Additionally, DIA significantly inhibited MRSA biofilm formation and disrupted pre - existing biofilms. Transcriptome analysis revealed 1,045 differentially expressed genes between the DIA-treated group and the control group, primarily involving pathways such as the tricarboxylic acid cycle, phosphorylation, ribosome metabolism, and nucleotide metabolism. Conclusion: In summary, DIA has antibacterial and anti-biofilm activities against MRSA and does not easily induce resistance. Its antibacterial mechanisms may involve multiple aspects, including bacterial protein synthesis, energy metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.